Clinical Trials on Refractory Pain

Total 25908 results

National Cancer Institute (NCI)

Active, not recruiting

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Sohag University

Recruiting

CPC in Adult Refractory Glaucoma

Refractory Glaucoma

Egypt
Helwan University

Completed

MicroPulse Transscleral Laser Cyclophotocoagulation With the Zig Zag Mode in Glaucoma.

Refractory Glaucoma

Egypt
University of Alabama at Birmingham

Completed

Mechanisms of Refractory Hypertension (Reserpine)

Refractory Hypertension

United States
Sequana Medical N.V.

Completed

ALFApump System Versus Standard of Care in Ascites Treatment

Refractory or Recurrent Ascites

Spain, United Kingdom, Italy, France, Austria
Targacept Inc.

Terminated

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

Refractory Hypertension

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Richter Syndrome and other conditions

United States
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Recurrent Renal Cell Carcinoma | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Malignant Solid Neoplasm | Rhabdoid Tumor | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Rhabdoid Tumor | Refractory Rhabdoid Tumor | Epithelioid Sarcoma | Kidney Medullary Carcinoma | Atypical Teratoid/Rhabdoid Tumor | Poorly Differentiated Chordoma | Recurrent Atypical... and other conditions

United States, Australia, Canada
Tang-Du Hospital

Completed

Early Transjugular Intrahepatic Portosystemic Shunts Improve Survival in Patients With Cirrhosis and Recurrent Ascites (TIPS)

Refractory Ascites

China
University of Southern California
National Institute of Mental Health (NIMH); University of California, San Francisco

Recruiting

Model-based Electrical Brain Stimulation

Medication Refractory Epilepsy Patients With Electrodes Already Implanted Based on Clinical Criteria for Standard Monitoring

United States
NextCure, Inc.

Recruiting

A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Chronic Myelomonocytic Leukemia | Relapsed or Refractory Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Advanced Rare Malignant Solid Neoplasm | Rare Malignant Solid Neoplasm | Refractory Rare Malignant Solid Neoplasm

United States
The Second Hospital of Shandong University

Not yet recruiting

NK Cell Therapy Recurrent/Refractory Elderly AML

AML | Elderly | Recurrent | Refractory

China
Association for Training, Education, and Research...

Active, not recruiting

Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders (LY-SET-HAPLO)

Refractory or Relapsed Lymphoid Haemopathy

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm

United States
Intezyne Technologies, Inc.

Terminated

Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer

Neoplasms | Cancer | Tumors | Refractory Solid Tumors | Recurrent Solid Tumors

United States
National Cardiovascular Center Harapan Kita Hospital...

Unknown

HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study (HARTEC)

Cardiac Rehabilitation | Angiogenesis | Refractory Angina

Indonesia
Eisai Inc.

Completed

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, Chile, Brazil, Canada, Mexico, Argentina
Eisai Inc.

Completed

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

United States, France, Germany, Italy, United Kingdom, Belgium, Israel, South Africa, Finland, Russian Federation, Austria, Netherlands, Sweden, India
Eisai Co., Ltd.

Completed

An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Refractory Partial Seizures

Japan
World Heart Corporation

Terminated

Levacor™ Ventricular Assist Device (VAD) Bridge to Transplant Study

Refractory Heart Failure

United States
Roswell Park Cancer Institute

Not yet recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
The First Affiliated Hospital of Xiamen University

Recruiting

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

Refractory Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

China
NeoImmuneTech

Recruiting

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

United States
Curis, Inc.
The Leukemia and Lymphoma Society

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Lymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditions

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

Relapsed Adult AML | Refractory AML

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma | Hematopoietic and Lymphatic System Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma
M.D. Anderson Cancer Center

Completed

Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies

Acute Myeloid Leukemia | Myeloproliferative Disorders | Chronic Myelomonocytic Leukemia | Anemia, Refractory, With Excess of Blasts

United States
Shenzhen Core Medical Technology CO.,LTD.

Not yet recruiting

Corheart 6 VAS Study

Refractory Heart Failure

Germany
Imperial College London
Medical Research Council; Imperial College Healthcare Nissen Fund

Recruiting

Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance (ORBITA-COSMIC)

Refractory Angina

United Kingdom
All India Institute of Medical Sciences, New Delhi
Council of Scientific and Industrial Research, India

Completed

Modified Atkins Diet in Childhood Epilepsy (mAD)

Refractory Childhood Epilepsy

India
National University Hospital, Singapore

Unknown

Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma

Advanced Glaucoma | Refractory Glaucoma

Singapore
Seattle Children's Hospital
Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics...

Completed

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

AML | Acute Leukemia of Ambiguous Lineage | ALL | Relapsed/Refractory AML | Relapsed/Refractory ALL | Secondary AML/MDS

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm

United States
TCRx Therapeutics Co.Ltd

Recruiting

KSH01-TCRT Solid Tumors (KSH01-TCRT)

Refractory Solid Tumors | Relapsed Solid Tumors | TCR-T Cells

China
National Cancer Institute (NCI)

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid Tumor

United States
Hutchmed

Completed

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

Relapsed or Refractory Lymphoma

United States

Clinical Trials on Refractory Pain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations